A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
Small Cell Lung Cancer (SCLC)
DRUG: Tarlatamab
Proportion of participants with confirmed objective response to Tarlatamab, Approximately 52 Months|Proportion of participants with complete response to Tarlatamab, Approximately 52 Months|Proportion of participants with partial response to Tarlatamab, Approximately 52 Months
Average serum concentrations of Tarlatamab, Approximately 52 Weeks|Duration of confirmed response, defined as the time from the first documentation of OR until the first documentation of disease progression or death, Approximately 52 Months|Disease control, defined as objective response or stable disease, Approximately 52 Months|Duration of disease control, Approximately 52 Months|Progression-free survival, defined as the time from randomization to the first documentation of disease progression or death due to any cause, Approximately 52 Months|Objective response, defined as best overall response of CR or PR, Approximately 52 Months|Overall survival, defined as the time from randomization to death due to any cause, Approximately 52 Months|Overall Survival rate at 6 months and 1 year from randomization, Approximately 52 Months|Number of participants with treatment-emergent adverse events, Approximately 52 Months|Number of participants with anti-tarlatamab antibody formation, Approximately 52 Months
The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).